NCT02491073View on ClinicalTrials.gov

Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)

CompletedOBSERVATIONAL
Enrollment

71

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Epilepsy
Interventions
OTHER

blood draw

Investigate the possibility of assay artifacts impacting the measurement of thyroid hormones, in particular FT4 and FT3, in ESL treated subjects compared to non-ESL-treated subjects.

Trial Locations (7)

10019

CliniLabs, New York

20817

Mid-Atlantic Epilepsy Center, Bethesda

40504

Bluegrass Epilepsy Research, Lexington

55422

Minneapolis Clinic of Neurology, Golden Valley

75251

NeurologicalClinic of Texas, P.A., Dallas

83702

Consultans in Epilepsy & Neurology, PLLC, Boise

85351

The More foundation/The Core Institute, Sun City

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT02491073 - Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL) | Biotech Hunter | Biotech Hunter